Company news

MoonLake Immunotherapeutics news in 2023

MoonLake Immunotherapeutics's news releases, calls and decks from 2023, newest first.

View company

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 13, 2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

November 4, 2023

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

October 14, 2023

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

October 10, 2023

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

October 3, 2023

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

September 5, 2023

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 9, 2023

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

July 24, 2023

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

June 27, 2023

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

June 25, 2023

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

June 24, 2023

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

May 2, 2023

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

April 18, 2023

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

March 19, 2023

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

February 1, 2023

Decks in 2023